The Pirbright Institute, Pirbright, United Kingdom.
The Pirbright Institute, Pirbright, United Kingdom
J Virol. 2018 Dec 10;93(1). doi: 10.1128/JVI.01627-18. Print 2019 Jan 1.
Avian influenza viruses continue to evolve and acquire mutations that facilitate antigenic drift and virulence change. In 2017, low-pathogenicity H7N9 avian influenza viruses evolved to a high-pathogenicity phenotype in China. Comparative antigenic analysis of the low- and high-pathogenicity virus strains showed marked variability. In order to identify residues that may be linked to the antigenic change among the H7N9 viruses, we serially passaged the viruses in the presence of homologous ferret antiserum. Progeny viruses able to overcome the neutralizing capacity of the antiserum were sequenced. The analysis showed that the emergent immune escape viruses contained mutations A125T, A151T, and L217Q in the hemagglutinin (HA) glycoprotein as early as passage 5 and that these mutations persisted until passage 10. The results revealed that a single mutation, L217Q, in the HA of H7N9 virus led to 23- and 8-fold reductions in hemagglutination inhibition (HI) titer with ferret and chicken antisera, respectively. Further analysis showed that this change also contributed to antigenic differences between the low- and high-pathogenicity H7N9 viruses, thus playing a major role in their antigenic diversification. Therefore, evolutionary changes at amino acid position 217 in the H7N9 viruses can serve as a genetic marker for virus antigenic diversity during vaccine seed matching and selection. The immune escape mutant selection method used in this study could also aid in the prediction of emerging antigenic variants in naturally infected or immunized animals. Avian influenza H7N9 viruses circulating in poultry and wild birds continue to evolve and acquire important phenotypic changes. Mutations to the virus hemagglutinin (HA) glycoprotein can modulate virus antigenicity and facilitate virus escape from natural or vaccine-induced immunity. The focus of this study was to identify evolutionary markers in the HA of H7N9 that drive escape from antibody-based immunity. To achieve this, we propagated low-pathogenicity H7N9 virus in the presence of polyclonal antiserum derived from ferrets infected with the same strain of virus (homologous antiserum). This selection process was repeated 10 times. The HA gene sequences of viruses recovered after the fifth passage showed that the viruses readily acquired mutations at three different amino acid positions (A125T, A151T, and L217Q). Further functional analysis of these mutations confirmed that the mutation at residue 217 in the HA was responsible for mediating changes to the immunological properties of the H7N9 virus.
禽流感病毒不断进化并获得突变,从而促进抗原漂移和毒力变化。2017 年,低致病性 H7N9 禽流感病毒在中国进化为高致病性表型。对低致病性和高致病性病毒株的比较抗原分析显示出明显的可变性。为了确定 H7N9 病毒之间可能与抗原变化相关的残基,我们在同源雪貂抗血清存在的情况下连续传代病毒。能够克服抗血清中和能力的后代病毒进行了测序。分析表明,早在第 5 代,出现的免疫逃逸病毒就在血凝素 (HA) 糖蛋白中包含 A125T、A151T 和 L217Q 突变,并且这些突变一直持续到第 10 代。结果表明,H7N9 病毒 HA 中的单个突变 L217Q 分别导致血凝抑制 (HI) 滴度与雪貂和鸡抗血清相比降低 23 倍和 8 倍。进一步分析表明,这种变化也导致了低致病性和高致病性 H7N9 病毒之间的抗原差异,因此在它们的抗原多样化中起主要作用。因此,H7N9 病毒中氨基酸位置 217 的进化变化可作为疫苗种子匹配和选择期间病毒抗原多样性的遗传标记。本研究中使用的免疫逃逸突变体选择方法也有助于预测自然感染或免疫动物中出现的新抗原变体。在禽类和野鸟中循环的禽流感 H7N9 病毒继续进化并获得重要的表型变化。病毒血凝素 (HA) 糖蛋白的突变可以调节病毒的抗原性并促进病毒逃避自然或疫苗诱导的免疫。本研究的重点是确定 H7N9 中逃避抗体免疫的 HA 中的进化标记。为了实现这一目标,我们在来自感染相同病毒株的雪貂的多克隆抗血清存在的情况下繁殖低致病性 H7N9 病毒(同源抗血清)。该选择过程重复了 10 次。第五次传代后回收的病毒 HA 基因序列表明,病毒很容易在三个不同的氨基酸位置(A125T、A151T 和 L217Q)获得突变。对这些突变的进一步功能分析证实,HA 中残基 217 的突变负责介导 H7N9 病毒免疫特性的变化。